[CVac is in this category and if it lists on N it would be nice to see such an article associated with Prima/CVac appear on people 'stock news' phone applications. Ovarian cancer has a large unmet need if there there was one.]
http://www.fool.com/investing/general/2011/10/28/invest-in-biotechs-going-after-unmet-needs.aspx
By Brian Orelli | More Articles
October 28, 2011 | Comments (0)
Wow!
Is there really any other way to describe the launch of Vertex Pharmaceuticals' (Nasdaq: VRTX ) hepatitis C drug Incivek?
We got a first peek at the launch in the second quarter, but that was only six weeks ago. The third quarter offered the first look at a full quarter of revenue. And what a quarter it was: $420 million in net sales of its new hepatitis C drug. Assuming nothing surprising pops up, Incivek will reach the magic $1 billion blockbuster status in its first 12 months on the market. That's easily the most successful launch in recent memory. Dendreon (Nasdaq: DNDN ) , Acorda Therapeutics (Nasdaq: ACOR ) , and Avanir Pharmaceuticals (Nasdaq: AVNR ) could learn a thing or two.
The unmet need of hepatitis C patients is a big reason for the successful launch of Incivek. The current treatments -- Roche's Pegasys and Merck's (NYSE: MRK ) PegIntron -- only cure about half of the patients they treat. Adding Incivek increases that number substantially and allows for a shorter duration of Pegasys or PegIntron, which is helpful given the nasty side effects of those drugs.
Keep in mind that unmet need may be necessary for a launch this successful, but it isn't sufficient to get you there. Incivek still had to post better cure rates than Merck's second-generation drug, Victrelis; if their efficacy had been similar, I'm not sure we'd be drooling over Incivek sales right now. Just look at Human Genome Sciences' (Nasdaq: HGSI ) Benlysta; it's the first new lupus treatment in 50 years, but sales last quarter were just $18.8 million, partially because doctors aren't convinced by the efficacy.
At a market cap topping $8.5 billion, there are still a lot of Incivek sales built in to Vertex's valuation. To grow further, Vertex has to keep growing sales of Incivek and gain approval for its cystic fibrosis drug Kalydeco next. A successful launch of that product would certainly help. But would you expect anything less? Cystic fibrosis is another unmet medical need.
- Forums
- ASX - By Stock
- IMM
- invest in biotechs going after unmet needs
invest in biotechs going after unmet needs
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $436.3M |
Open | High | Low | Value | Volume |
30.0¢ | 30.5¢ | 29.5¢ | $1.339M | 4.459M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 70497 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 15625 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 70497 | 0.300 |
14 | 472443 | 0.295 |
14 | 307298 | 0.290 |
8 | 1041774 | 0.285 |
15 | 387629 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 15625 | 1 |
0.310 | 166851 | 8 |
0.315 | 8163 | 3 |
0.320 | 86811 | 4 |
0.325 | 236471 | 3 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online